Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-27. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
== Market operations == Nachash, former proprietor of Doxbin, wrote a guide in early 2015 entitled So, You Want To Be a Darknet Drug Lord ... Background research tasks included learning from past drug lords, researching legal matters, studying law enforcement agency tactics and obtaining legal representation. With regards to the prospective market's hosting, he recommends identifying a hosting country with gaps in their mutual legal assistance treaty with one's country of residence, avoiding overpriced bulletproof hosting and choosing a web host with Tor support that accepts suitably hard-to-trace payment. Patterns recommended to avoid include hiring hitmen like Dread Pirate Roberts, and sharing handles for software questions on sites like Stack Exchange. He advises on running a secured server operating system with a server-side transparent Tor proxy server, hardening web application configurations, Tor-based server administration, automated server configuration management rebuild and secure destruction with frequent server relocation rather than a darknet managed hosting service. To protect against guard node deanonymization he recommends obfuscating traffic by investing in Tor relays which the market site will exclusively use. For a local machine configuration, he recommends a computer purchased for cash running Linux, using a local Tor transparent proxy. For operations security he suggests avoiding storing conversation logs, varying writing styles, avoiding mobile phone-based tracking and leaking false personal details to further obfuscate one's identity.
=== Metallic === Metallic nanoparticles may be beneficial for some technical applications due to their higher magnetic moment whereas oxides (maghemite, magnetite) would be beneficial for biomedical applications. This also implies that for the same moment, metallic nanoparticles can be made smaller than their oxide counterparts. On the other hand, metallic nanoparticles have the great disadvantage of being pyrophoric and reactive to oxidizing agents to various degrees. This makes their handling difficult and enables unwanted side reactions which makes them less appropriate for biomedical applications. Colloid formation for metallic particles is also much more challenging.
== Illicit production == Illicit production and sale of etonitazene has been limited. Identified on the Moscow illegal drug market in 1998, it was primarily smoked in laced cigarettes. A chemist at Morton Thiokol synthesized the compound for his own use. The drug was produced in Russia in 1996 and sold as 'Chinese Dwarf'. The drug resulted in an unconfirmed number of deaths due to its uncertain potency. Etonitazene appears to have a steep dose-response curve, and unpredictable pharmacokinetics especially when injected, in a similar manner to some other potent opioids such as dextromoramide, which may cause etonitazene to be especially hazardous when compared to opioids of similar potency such as fentanyl.
== Early life == William Cumming Rose was born in Greenville, South Carolina. He attended various local schools, but his father John M. Rose, who was a Presbyterian minister, began to homeschool William in Latin, Greek, and Hebrew when he was 14 years old. He also studied an introductory chemistry textbook by Ira Remsen. When he was 16, he studied at Davidson College in North Carolina for his bachelor's degree. He took up graduate education at Yale University studying food chemistry with Russell Chittenden and Lafayette Mendel. He was granted a PhD in 1911.
Sources: en.wikipedia.org
Alloxan, sometimes referred to as alloxan monohydrate, is an organic compound with the formula OC(NHCO)2C(OH)2. It is classified as a derivative of pyrimidine. The anhydrous derivative OC(NHCO)2CO is also known, as well as a dimeric derivative. These are some of the earliest known organic compounds. They exhibit a variety of biological activities.
=== Randomized clinical trials === Randomized controlled trials have compared TOPS to lumbar fusion in patients with lumbar spinal stenosis and grade I degenerative spondylolisthesis. In a large multicenter trial, TOPS demonstrated significantly higher rates of clinical success compared with fusion at two years. Three-year results from the same randomized multicenter investigational device exemption study reported composite clinical success in 76.0% of patients treated with TOPS and 56.8% of patients treated with fusion.
{\displaystyle {{\frac {q}{A}}_{min}}=C{{h}_{fg}}{{\rho }_{v}}{{\left[{\frac {\sigma g\left({{\rho }_{L}}-{{\rho }_{v}}\right)}{{\left({{\rho }_{L}}+{{\rho }_{v}}\right)}^{2}}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{4}\;}}}
=== Pharmacodynamics === Dihydroergotamine's antimigraine activity is due to its action as an agonist at the serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors. It also interacts with other serotonin, adrenergic, and dopamine receptors. Dihydroergotamine is an agonist of the serotonin 5-HT2B receptor and has been associated with cardiac valvulopathy. In spite of acting as an agonist of the serotonin 5-HT2A receptor, dihydroergotamine has been described as non-hallucinogenic. This is also the case with certain other ergoline derivatives, such as bromocriptine and pergolide.
=== Cardioprotective activity === Didymin has been shown to protect against doxorubicin-induced cardiotoxicity in mouse models and cardiomyocyte cell cultures, reducing oxidative stress, mitochondrial dysfunction, and apoptosis via activation of the PI3K/Akt/Nrf2 signalling pathway. In endothelial cell studies, didymin prevented hyperglycaemia-induced dysfunction and death in human umbilical vein endothelial cells (HUVECs) by reducing ROS generation, lipid peroxidation, and inflammatory cytokine release, and by inhibiting NF-κB activation.
Sources: en.wikipedia.org
As of November 2024 he is not listed as part of the National Institute on Aging's staff on their website, although in November 2024 his name still appeared in NIH's Network Enterprise Directory, suggesting he was still an NIH employee.
From time to time, the operator would remove the bulb and shake it, allowing the tungsten powder to scrub off most of the tungsten that had condensed on the interior of the envelope, removing the blackening and brightening the lamp again.
This broad classification is based on the empirical makeup and atomic structure of the solid materials, and most solids fall into one of these broad categories. An item that is often made from each of these materials types is the beverage container. The material types used for beverage containers accordingly provide different advantages and disadvantages, depending on the material used. Ceramic (glass) containers are optically transparent, impervious to the passage of carbon dioxide, relatively inexpensive, and are easily recycled, but are also heavy and fracture easily. Metal (aluminum alloy) is relatively strong, is a good barrier to the diffusion of carbon dioxide, and is easily recycled. However, the cans are opaque, expensive to produce, and are easily dented and punctured. Polymers (polyethylene plastic) are relatively strong, can be optically transparent, are inexpensive and lightweight, and can be recyclable, but are not as impervious to the passage of carbon dioxide as aluminum and glass.
== Low-cost laboratory automation == A large obstacle to the implementation of automation in laboratories has been its high cost. Many laboratory instruments are very expensive. This is justifiable in many cases, as such equipment can perform very specific tasks employing cutting-edge technology. However, there are devices employed in the laboratory that are not highly technological but still are very expensive. This is the case of many automated devices, which perform tasks that could easily be done by simple and low-cost devices like simple robotic arms, universal (open-source) electronic modules, Lego Mindstorms, or 3D printers. So far, using such low-cost devices together with laboratory equipment was considered to be difficult. However, it has been demonstrated that such low-cost devices can substitute for the standard machines used in laboratory without problems. It can be anticipated that more laboratories will take advantage of this as low-cost automation is very attractive for laboratories. A technology that enables the integration of any machine regardless of their brand is scripting, more specifically, scripting involving the control of mouse clicks and keyboard entries, like AutoIt. By timing clicks and keyboard inputs, different software interfaces controlling different devices can be perfectly synchronized.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.